OOIR: Observatory of International Research

Papers

(The TQCC of Translational Neurodegeneration is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	267
Exploring the skin as an open window onto neurodegenerative diseases	177
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	175
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	173
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	162
Attenuating α-synuclein pathology in mice with in situ engineered astrocytes	161
Age-dependent removal of Atg9-containing vesicle accumulations in motoneuron disease models by physical exercise	130
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	130
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	127
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	125
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	120
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	110
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	97
Role of dopamine in the pathophysiology of Parkinson’s disease	94
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	91
Axonopathy: mechanisms and potential therapeutic targets for neurodegenerative diseases	91
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	88
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	85
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	85
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	81
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	80
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	77
Cortical layer multi-parameter analysis of neurovascular impairments in AD/ADRD rodent model with in vivo optical imaging	75
Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	75
Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease	74

Functional analysis of late-onset Alzheimer’s disease risk genes in Caenorhabditis elegans identifies regulators of neuronal aging	73
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	72
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	68
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	60
Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications	58
Inflammasomes in neurodegenerative diseases	57
Nose-to-brain drug delivery: from bench to bedside	57
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	55
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	54
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	52
Peripheral proteinopathy in neurodegenerative diseases	52
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	50
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	49
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	47
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	47
Transaldolase 1 contributes to pentose phosphate pathway disruption and synaptic dysfunction in Alzheimer’s disease	46
Mesenchymal stromal cells and neuroinflammation: a multimodal approach to neuroprotection and future therapeutic horizons	46
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	46
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	46
The emerging role and therapeutic targeting of autophagy-lysosome pathway in the pathogenesis of Parkinson’s disease	44
Molecular mechanisms of exercise-induced improvements in Alzheimer’s disease: a focus on lipid homeostasis	43
Multidimensional biomarkers for multiple system atrophy: an update and future directions	43
Perivascular spaces relate to the course and cognition of Huntington’s disease	42
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	41
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases	40
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	40
Aging-dependent YAP1 reduction contributes to AD pathology by upregulating the Nr4a1-AKT/GSK-3β axis	39
Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	38
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	38
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	38
Tau conformation, distribution and PET imaging correlations in progressive supranuclear palsy	38
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	37
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	37
Deficient AMPK-SENP1-Sirt3 signaling impairs mitochondrial complex I function in Parkinson’s disease model	36
Role of extracellular vesicle-carried ncRNAs in the interactive ‘dialogue’ within the brain and beyond: emerging theranostic epigenetic modifiers in brain-derived nanoplatforms	35
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	35
Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease	33
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	32
Mapping cellular vulnerability in Parkinson’s disease using retro-AAVs and preformed α-synuclein fibrils	32
In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use	31
Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease	31
Plasma proteomic signatures as predictors of dementia risk in individuals with sleep apnea: a cohort study	31